These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8818125)

  • 21. Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia.
    O'Sullivan M; Murphy C; Deasy C; Iohom G; Kiely EA; Shorten G
    J Am Coll Surg; 2004 Mar; 198(3):394-403. PubMed ID: 14992742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimally invasive prostatic urethral lift: surgical technique and multinational experience.
    McNicholas TA; Woo HH; Chin PT; Bolton D; Fernández Arjona M; Sievert KD; Schoenthaler M; Wetterauer U; Vrijhof EJ; Gange S; Montorsi F
    Eur Urol; 2013 Aug; 64(2):292-9. PubMed ID: 23357348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benign prostatic hyperplasia: a review.
    Ramsey EW
    Can J Urol; 2000 Dec; 7(6):1135-43. PubMed ID: 11151094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens].
    Zhang YG; Wang JY; Liu M; Wan B; Wei D; Deng SM; Xu J; Wu JY; Chu X; Zeng P
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1690-2. PubMed ID: 19024540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison.
    Geavlete B; Stanescu F; Iacoboaie C; Geavlete P
    BJU Int; 2013 May; 111(5):793-803. PubMed ID: 23469933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate.
    Qian X; Yu G; Qian Y; Xu D; Liu H; Kong X; Zhu Y; Wang Z; Zheng J; Qi J
    Aging Male; 2015; 18(4):238-43. PubMed ID: 26225794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer.
    Brundage MD; Davidson JR; Mackillop WJ; Feldman-Stewart D; Groome P
    Med Decis Making; 1998; 18(3):256-67. PubMed ID: 9679990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the treatment of benign prostatic hyperplasia.
    Lai MK
    J Formos Med Assoc; 1996 Nov; 95(11):822-7. PubMed ID: 8990768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.
    Kaplan SA; Goluboff ET; Olsson CA; Deverka PA; Chmiel JJ
    Urology; 1995 Mar; 45(3):398-405. PubMed ID: 7533451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Symptom severity and patients' values in the decision to perform a transurethral resection of the prostate.
    Krumins PE; Fihn SD; Kent DL
    Med Decis Making; 1988; 8(1):1-8. PubMed ID: 2448577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation.
    Grise P; Plante M; Palmer J; Martinez-Sagarra J; Hernandez C; Schettini M; Gonzalez-Martin M; Castiñeiras J; Ballanger P; Teillac P; Rolo F; Baena V; Erdmann J; Mirone V
    Eur Urol; 2004 Oct; 46(4):496-501; discussion 501-2. PubMed ID: 15363567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes.
    MacKeigan LD; O'Brien BJ; Oh PI
    Med Decis Making; 1999; 19(2):113-21. PubMed ID: 10231073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of the BSP-BPH (Bononian Satisfaction Profile--Benign Prostatic Hyperplasia) a "disease-specific" questionnaire for the evaluation of health related quality of life in patients with benign prostatic hyperplasia.
    Bertaccini A; Martinelli A; Ceccarelli R; Palmieri F; Vitullo G; Urbinati M; Marchiori D; Costal F; Martorana G
    Arch Ital Urol Androl; 2004 Sep; 76(3):103-9. PubMed ID: 15568297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.
    Barry MJ; Fowler FJ; O'Leary MP; Bruskewitz RC; Holtgrewe HL; Mebust WK
    Med Care; 1995 Apr; 33(4 Suppl):AS145-55. PubMed ID: 7536866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs).
    Brunner HI; Maker D; Grundland B; Young NL; Blanchette V; Stain AM; Feldman BM
    Med Decis Making; 2003; 23(4):314-22. PubMed ID: 12926581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
    BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.